1,086 material Form 8-K filings that 883 companies we cover made with the SEC in July 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Biogen said its preliminary second-quarter 2025 GAAP and non-GAAP results will include about $46 million in pre-tax acquired in-process R&D, upfront and milestone expense. That charge is expected to reduce diluted earnings per share by about $0.26. Biogen also said the quarter's results have not been finalized and could differ from these estimates.
Estimated pre-tax acquired in-process R&D, upfront and milestone expense: about $46 million for the quarter ended June 30, 2025
Expected impact on GAAP and non-GAAP diluted EPS: about ($0.26) per share
Biogen does not forecast this expense because the timing and size of such deals are uncertain; Q2 results remain subject to closing procedures
Strategy reported an unrealized gain on digital assets of $14.05 billion for the quarter ended June 30, 2025, but also recorded an associated deferred tax expense of $4.04 billion. The filing shows $6.8 billion in aggregate net proceeds from capital markets transactions in the quarter, and the company held 597,325 bitcoin as of July 6, 2025, with no bitcoin acquired in the July 1 to July 6 period. The financial information is unaudited, as KPMG LLP has not audited or reviewed it.
Unrealized gain on digital assets of $14.05 billion in Q2 2025, with deferred tax expense of $4.04 billion
Digital asset carrying value of $64.36 billion as of June 30, 2025, with a related deferred tax liability of $6.31 billion
Aggregate net proceeds of $6.8 billion received in Q2 2025 from preferred stock and common stock programs
Bitcoin holdings of 597,325 as of July 6, 2025, with no bitcoin acquired from June 30 to July 6, 2025
Molina Healthcare said preliminary second-quarter 2025 adjusted earnings are about $5.50 per share, modestly below its prior expectations, citing medical cost pressures in all three lines of business. It also updated full-year 2025 adjusted EPS guidance to $21.50 to $22.50, a consolidated pre-tax margin of just under 4%, which is the low end of its long-term range, and expects the cost pressures to continue into the second half.
Preliminary Q2 2025 adjusted EPS of approximately $5.50; GAAP net income of approximately $259 million, or $4.83 per diluted share
Full-year 2025 adjusted EPS guidance of $21.50 to $22.50, versus GAAP net income guidance of $1,045 million to $1,099 million
Medical cost pressures expected to continue into the second half of 2025
Full second-quarter results to be released after market close on July 23, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.